|
First dose
|
n = 24,723
|
n = 53,558
|
|
Week of age at vaccination (median; IQR)
|
9 (9–11)
|
9 (9–10)
|
|
Dose administration >12 weeksa (n; %)
|
5,263 (21%)
|
6,515(12%)
|
|
Second dose
|
n = 21,119
|
n = 44,995
|
|
Week of age at vaccination (median; IQR)
|
18 (17–19)
|
17 (15–18)
|
|
Dose administration >24 weeksb (n; %)
|
1,172 (6%)
|
-
|
|
1st - 2nd dose interval in weeks (median; IQR)
|
9 (8–9)
|
8 (5–9)
|
|
1st - 2nd dose interval 22–27 days (n; %)
|
213 (1%)
|
1,162 (3%)
|
|
Third dose
|
-
|
n = 34,865
|
|
Week of age at vaccination (median; IQR)
|
-
|
26 (19–27)
|
|
Dose administration >32 weeksc (n; %)
|
-
|
179 (1%)
|
|
2nd – 3rd dose interval in weeks (median; IQR)
|
-
|
8 (5–9)
|
|
2nd – 3rd dose interval 22–27 days (n; %)
|
-
|
1,338 (4%)
|
